TRAW

Traws Pharma, Inc.
CAPPED RATING

Traws Pharma, Inc. (TRAW) is rated D+ (1.8/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B+); its weakest is Profitability (D-).

Quantitative Factor Evaluation • Updated

Overall Rating
1.8 / 5.0
D+
Value
B+
Factor Score 3.7 / 5.0
Growth
D
Factor Score 1.2 / 5.0
Profitability
D-
Factor Score 0.8 / 5.0
Momentum
D-
Factor Score 0.8 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -0.1
EV / EBITDA 0.1
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -53.7%
Price Return 12M -88.3%
Catalyst Signal 0.00
Market Cap $3.9M
TTM Revenue $0.0
Price / Sales N/A
ROE -433.4%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-15 B+ (3.7) D (1.2) D- (0.8) D- (0.8) C+ (2.6) D+ (1.8)
2026-11-08 A- (3.9) D (1.2) D- (0.8) F (0.7) C+ (2.6) D+ (1.8)
2026-11-01 B+ (3.7) D (1.2) D- (1.0) D (1.2) C+ (2.7) C- (1.9)
2026-10-25 C+ (2.5) D (1.2) D- (0.9) D (1.2) C+ (2.6) D+ (1.7)
2026-10-18 C+ (2.5) D (1.2) D- (0.9) D- (1.1) C+ (2.6) D+ (1.7)
Page 1 of 3